Focusing on changing clinical practice to enhance rational prescribing - Collaboration and networking enable comprehensive approaches

Health Policy

Volumn 66, Issue 1, 2003, Pages 1-10

  Helin Salmivaara, Arja ^a   Huupponen, Risto ^b   Klaukka, Timo ^c   Hoppu, Kalle ^d  

^a Finska Lo karforeningen Duodecim   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c SOCIAL INSURANCE INSTITUTION   (Finland)

^d Poison Information Centre   (Finland)

Author keywords

Collaboration; Continuing medical education; Rational prescribing; Strategy

Indexed keywords

CLINICAL PRACTICE; CONTINUING EDUCATION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FEEDBACK SYSTEM; FINLAND; GOVERNMENT; HEALTH PROGRAM; HUMAN; MEDICAL EDUCATION; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; TREATMENT OUTCOME;

EID: 0141677028     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8510(03)00020-4     Document Type: Article

References (28)

1. Psaty B.M., Smith N.L., Siscovick D.S., Koepsell T.D., Weiss N.S., Heckbert S.R., et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. Journal of the American Medical Association. 277:1997;739-745.
2. Wright J.M., Lee C.-H., Chambers G.K. Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug. Canadian Medical Association Journal. 161:1999;25-32.
3. Messerli F.H., Grossman E., Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. Journal of the American Medical Association. 279:1998;1903-1907.
4. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. New England Journal of Medicine. 325:1991;293-302.
5. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. New England Journal of Medicine. 334:1996;1349-1355.
6. Randomised trial of cholesterol lowering in 4444 patients with coronary hearth disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
7. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary hearth disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. New England Journal of Medicine. 333:1995;1301-1307.
8. Rogers S.L., Friedhoff L.T. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. European Psychopharmacology. 8:1998;67-75.
9. Rösler M., Anand R., Cicin-Sain A., Gauthier S., Agid Y., Dal-Bianco D., et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. British Medical Journal. 318:1999;633-640.
10. Palmer A.M. Pharmacotherapy for Alzheimer disease: progress and prospects. Trends in Pharmacological Sciences. 23:2002;426-433.
11. Rice G.A., Incorvaia B., Munari L., Ebers G., Polman C., D'Amico R., Filippini G. Interferon in relapsing-remitting multiple sclerosis (Cochrane Review). The Cochrane library, issue 1. 2002;Update Software, Oxford.
12. Moynihan R., Heath I., Henry D. Selling sickness: the pharmaceutical industry and disease mongering. British Medical Journal. 324:2002;886-891.
13. Purves I. PRODIGY: implementing clinical guidance using computers. Br J Gen Pract 1998;48:1552-3.
14. Ekedahl A., Petersson B.-Å., Eklund P., Rametsteiner G., Melander A. Prescribing patterns and drug costs: effects of formulary recommendations and continuity pharmacists' information campaigns. International Journal of Pharmaceutics. 2:1994;194-198.
15. Håkanson A., Andersson H., Cars H., Melander A. Prescribing, prescription costs and adherence to formulary committee recommendations: long term differences between physicians in public and private care. European Journal of Clinical Pharmcology. 57:2001;65-70.
16. de Vries S. Collaboration in health care; the tango to drug safety [dissertation]. Groningen: University of Groningen, 1998.
17. Soumerai S.B., McLaughlin T.J., Avorn J. Improving drug prescribing in primary care: a critical analysis of the experimental literature. The Milbank Quarterly. 67:1989;268-317.
18. Grimshaw J.M., Russel I.T. Effect of clinical guidelines on medical practice. A systematic review of rigorous evaluations. Lancet. 342:1993;1317-1322.
19. Wensing M., Grol R. Single and combined strategies for implementing changes in primary care: a literature review. Quality of Health Care. 6:1994;115-132.
20. Davis D.A., Thomson M.A., Oxman A.D., Haynes R.B. Changing physician performance: a systematic review of the effect of CME strategies. Journal of the American Medical Association. 274:1995;700-705.
21. Grol R. Beliefs and evidence in changing clinical practice. British Medical Journal. 315:1997;418-421.
22. Hermanson T., Aro S., Bennet C.L. Finland's health care system. Universal access to health care in a capitalistic democracy. Journal of the American Medical Association. 271:1994;1957-1962.
23. Mäkelä M., Kunnamo I. Evidence-based clinical guidelines. Duodecim. 344:1997;1276-1322. (in Finnish).
24. Nikkarinen T, Huvinen S, Brommels M. National consensus and local consideration. Changing the prescription practices by means of training. Evaluation Report of the ROHTO Project. Reports of the Ministry of Social Affairs and Health, 2002:1. Helsinki; 2002 (in Finnish).
25. Cheren M. CME as coaching - CME director as coach. J. Cont. Educ. Health Prof. 19:1999;250-252.
26. Bradley C.P. Uncomfortable prescribing decisions: a critical incident study. British Medical Journal. 304:1992;294-296.
27. Armstrong D., Reyburn H., Jones R. A study of general practitioners' reasons for changing their prescribing behaviour. British Medical Journal. 312:1996;949-952.
28. Fox R.D., Miner C. Motivation and the facilitation of change, learning, and participation in educational programs for health professionals. J. Cont. Educ. Health Prof. 19:1999;132-141.